• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CB1 T210的突变产生活性和非活性受体形式:与配体亲和力、受体稳定性和细胞定位的相关性。

Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization.

作者信息

D'Antona Aaron M, Ahn Kwang H, Kendall Debra A

机构信息

Department of Molecular and Cell Biology, University of Connecticut, Storrs, Connecticut 06269-3125, USA.

出版信息

Biochemistry. 2006 May 2;45(17):5606-17. doi: 10.1021/bi060067k.

DOI:10.1021/bi060067k
PMID:16634642
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2667143/
Abstract

Human cannabinoid receptor 1 (CB(1)) has attracted substantial interest as a potential therapeutic target for treating obesity and other obsessive disorders. An understanding of the mechanism governing the transition of the CB(1) receptor between its inactive and active states is critical for understanding how therapeutics can selectively regulate receptor activity. We have examined the importance of the Thr at position 210 in CB(1) in this transition, a residue predicted to be on the same face of the helix as the Arg of the DRY motif highly conserved in the G protein-coupled receptor superfamily. This Thr was substituted with Ile and Ala via mutagenesis, and the receptors, T210I and T210A, were expressed in HEK 293 cells. The T210I receptor exhibited enhanced agonist and diminished inverse agonist affinity relative to the wild type, consistent with a shift toward the active form. However, treatment with GTPgammaS to inhibit G protein coupling diminished the affinity change for the inverse agonist SR141716A. The decreased thermal stability of the T210I receptor and increased level of internalization of a T210I receptor-GFP chimera were also observed, consistent with constitutive activity. In contrast, the T210A receptor exhibited the opposite profile: diminished agonist and enhanced inverse agonist affinity. The T210A receptor was found to be more thermally stable than the wild type, and high levels of a T210A receptor-GFP chimera were localized to the cell surface as predicted for an inactive receptor form. These results suggest that T210 plays a key role in governing the transition between inactive and active CB(1) receptor states.

摘要

人类大麻素受体1(CB(1))作为治疗肥胖症和其他强迫性疾病的潜在治疗靶点,已引起了广泛关注。了解CB(1)受体在其非活性状态和活性状态之间转换的机制,对于理解治疗药物如何选择性调节受体活性至关重要。我们研究了CB(1)中第210位苏氨酸(Thr)在这种转换中的重要性,该残基预计与G蛋白偶联受体超家族中高度保守的DRY基序的精氨酸位于螺旋的同一面上。通过诱变将该苏氨酸替换为异亮氨酸(Ile)和丙氨酸(Ala),并在HEK 293细胞中表达受体T210I和T210A。与野生型相比,T210I受体表现出增强的激动剂亲和力和减弱的反向激动剂亲和力,这与向活性形式的转变一致。然而,用GTPγS处理以抑制G蛋白偶联,可减少反向激动剂SR141716A的亲和力变化。还观察到T210I受体的热稳定性降低以及T210I受体-GFP嵌合体的内化水平增加,这与组成型活性一致。相比之下,T210A受体表现出相反的特征:激动剂亲和力减弱,反向激动剂亲和力增强。发现T210A受体比野生型更热稳定,并且高水平的T210A受体-GFP嵌合体如预测的非活性受体形式一样定位于细胞表面。这些结果表明,T210在控制CB(1)受体非活性状态和活性状态之间的转换中起关键作用。

相似文献

1
Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization.CB1 T210的突变产生活性和非活性受体形式:与配体亲和力、受体稳定性和细胞定位的相关性。
Biochemistry. 2006 May 2;45(17):5606-17. doi: 10.1021/bi060067k.
2
A cannabinoid receptor 1 mutation proximal to the DRY motif results in constitutive activity and reveals intramolecular interactions involved in receptor activation.DRY 基序附近的大麻素受体 1 突变导致组成型活性,并揭示了受体激活过程中涉及的分子内相互作用。
Brain Res. 2006 Sep 7;1108(1):1-11. doi: 10.1016/j.brainres.2006.05.042. Epub 2006 Jul 31.
3
Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.变构调节剂 ORG27569 诱导 CB1 大麻素受体高亲和力激动剂结合状态、受体内化和 Gi 蛋白非依赖性 ERK1/2 激酶激活。
J Biol Chem. 2012 Apr 6;287(15):12070-82. doi: 10.1074/jbc.M111.316463. Epub 2012 Feb 16.
4
3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.3-取代吡唑类大麻素 1 型受体(CB₁)拮抗剂利莫那班类似物:通过非 CB₁、非 CB₂机制在小鼠中产生类大麻素激动剂样作用。
J Pharmacol Exp Ther. 2012 Feb;340(2):433-44. doi: 10.1124/jpet.111.187815. Epub 2011 Nov 15.
5
The G protein-coupled cannabinoid-1 (CB1) receptor of mammalian brain: inhibition by phthalate esters in vitro.哺乳动物脑内的 G 蛋白偶联大麻素-1(CB1)受体:邻苯二甲酸酯在体外的抑制作用。
Neurochem Int. 2011 Oct;59(5):706-13. doi: 10.1016/j.neuint.2011.06.019. Epub 2011 Jul 7.
6
An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.大麻素CB(1)受体上的一个芳香微区构成激动剂/反向激动剂结合区域。
J Med Chem. 2003 Nov 20;46(24):5139-52. doi: 10.1021/jm0302647.
7
Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.鞘氨醇及其类似物,即免疫抑制剂2-氨基-2-(2-[4-辛基苯基]乙基)-1,3-丙二醇,可与CB1大麻素受体相互作用。
Mol Pharmacol. 2006 Jul;70(1):41-50. doi: 10.1124/mol.105.020552. Epub 2006 Mar 29.
8
O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus.O-2050促进去甲肾上腺素释放,并增强利莫那班在豚鼠海马体中的CB1受体反向激动作用。
Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):621-8. doi: 10.1007/s00210-014-0991-3. Epub 2014 May 23.
9
Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2.新型内源性大麻素受体 CB1 信号转导研究进展:细胞外第三环与跨膜螺旋 2 之间关键相互作用的发现
J Pharmacol Exp Ther. 2013 May;345(2):189-97. doi: 10.1124/jpet.112.201046. Epub 2013 Feb 20.
10
The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.利莫那班对 G 蛋白激活的反向激动作用不是通过大麻素 CB1 受体介导的:来自尸检人脑的证据。
Biochem Pharmacol. 2012 Jan 15;83(2):260-8. doi: 10.1016/j.bcp.2011.10.018. Epub 2011 Nov 7.

引用本文的文献

1
Crystal structures of agonist-bound human cannabinoid receptor CB.激动剂结合型人大麻素受体CB的晶体结构
Nature. 2025 Aug 27. doi: 10.1038/s41586-025-09454-5.
2
Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1.大麻素受体 CB1 的变构调节的分子机制。
Nat Chem Biol. 2022 Aug;18(8):831-840. doi: 10.1038/s41589-022-01038-y. Epub 2022 May 30.
3
CB1 Cannabinoid Receptor Signaling and Biased Signaling.大麻素 CB1 受体信号转导与偏向信号转导。

本文引用的文献

1
Pharmacotherapy for obesity--promise and uncertainty.肥胖症的药物治疗——前景与不确定性。
N Engl J Med. 2005 Nov 17;353(20):2187-9. doi: 10.1056/NEJMe058243.
2
The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes.大麻素CB1受体拮抗剂利莫那班(SR141716)可抑制培养的小鼠3T3 F442A前脂肪细胞的细胞增殖,并增加脂肪细胞成熟标志物。
Mol Pharmacol. 2006 Feb;69(2):471-8. doi: 10.1124/mol.105.015040. Epub 2005 Nov 9.
3
A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders.
Molecules. 2021 Sep 6;26(17):5413. doi: 10.3390/molecules26175413.
4
In Vitro and In Silico Characterization of G-Protein Coupled Receptor (GPCR) Targets of Phlorofucofuroeckol-A and Dieckol.Phlorofucofuroeckol-A 和 Dieckol 作用的 G 蛋白偶联受体 (GPCR) 靶点的体外和计算研究
Mar Drugs. 2021 Jun 4;19(6):326. doi: 10.3390/md19060326.
5
A novel bioassay for quantification of surface Cannabinoid receptor 1 expression.一种用于定量检测表面大麻素受体 1 表达的新型生物测定法。
Sci Rep. 2020 Oct 23;10(1):18191. doi: 10.1038/s41598-020-75331-y.
6
Protein Interactors and Trafficking Pathways That Regulate the Cannabinoid Type 1 Receptor (CB1R).调节1型大麻素受体(CB1R)的蛋白质相互作用分子及运输途径
Front Mol Neurosci. 2020 Jun 12;13:108. doi: 10.3389/fnmol.2020.00108. eCollection 2020.
7
Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-G Complex Structures.大麻素受体-G 复合物结构揭示的激活和信号转导机制。
Cell. 2020 Feb 20;180(4):655-665.e18. doi: 10.1016/j.cell.2020.01.008. Epub 2020 Jan 30.
8
Probing thermostability of detergent-solubilized CB receptor by parallel G protein-activation and ligand-binding assays.通过平行的 G 蛋白激活和配体结合测定法探测去污剂增溶 CB 受体的热稳定性。
J Biol Chem. 2020 Jan 3;295(1):181-190. doi: 10.1074/jbc.RA119.010696. Epub 2019 Nov 27.
9
Allosteric modulators restore orthosteric agonist binding to mutated CB receptors.变构调节剂恢复了突变 CB 受体的正构激动剂结合。
J Pharm Pharmacol. 2020 Jan;72(1):84-91. doi: 10.1111/jphp.13193. Epub 2019 Nov 13.
10
Structural Insights into CB1 Receptor Biased Signaling.结构洞察大麻素 CB1 受体偏向信号传导。
Int J Mol Sci. 2019 Apr 13;20(8):1837. doi: 10.3390/ijms20081837.
大麻素CB1受体拮抗剂在重度抑郁症中的治疗作用。
Trends Pharmacol Sci. 2005 Dec;26(12):609-17. doi: 10.1016/j.tips.2005.10.006. Epub 2005 Nov 2.
4
The DRY motif as a molecular switch of the human oxytocin receptor.作为人催产素受体分子开关的DRY基序。
Biochemistry. 2005 Aug 2;44(30):9990-10008. doi: 10.1021/bi0509853.
5
Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding.人类大麻素受体中的半胱氨酸残基:功能性受体仅需要C257和C264,且C386处的空间位阻会损害拮抗剂SR141716A的结合。
Biochemistry. 2005 Jun 21;44(24):8757-69. doi: 10.1021/bi0472651.
6
CB1 receptor antagonists for the treatment of nicotine addiction.用于治疗尼古丁成瘾的CB1受体拮抗剂。
Pharmacol Biochem Behav. 2005 Jun;81(2):387-95. doi: 10.1016/j.pbb.2005.01.024.
7
High constitutive activity of a virus-encoded seven transmembrane receptor in the absence of the conserved DRY motif (Asp-Arg-Tyr) in transmembrane helix 3.在跨膜螺旋3中缺乏保守的DRY基序(天冬氨酸-精氨酸-酪氨酸)的情况下,一种病毒编码的七跨膜受体具有高组成活性。
Mol Pharmacol. 2005 Jul;68(1):11-9. doi: 10.1124/mol.105.011239. Epub 2005 Mar 23.
8
Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions.化学性质不同的配体促进CB1大麻素受体与Gi蛋白的差异性相互作用。
Mol Pharmacol. 2005 Jun;67(6):2016-24. doi: 10.1124/mol.104.003558. Epub 2005 Mar 4.
9
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?大麻素CB1受体和多巴胺D2受体的同时刺激增强异二聚体形成:一种受体相互作用的机制?
Mol Pharmacol. 2005 May;67(5):1697-704. doi: 10.1124/mol.104.006882. Epub 2005 Feb 14.
10
Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence.大麻素CB1受体拮抗剂作为治疗药物依赖的有前景的新型药物。
J Pharmacol Exp Ther. 2005 Mar;312(3):875-83. doi: 10.1124/jpet.104.077974. Epub 2004 Nov 3.